ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.79832
-0.71%
Brent Oil
83.95
0.47%
Bitcoin
62,683.39
2.44%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Imunon Inc (IMNN)

  7. Imunon Inc (IMNN) Noticias

IMNN

Imunon (IMNN)

Imunon Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMNN
FechaHoraFuenteTítuloSímboloCompañía
08/05/202407:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
08/05/202407:00GlobeNewswire Inc.IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEONASDAQ:IMNNImunon Inc
06/05/202410:00GlobeNewswire Inc.IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024NASDAQ:IMNNImunon Inc
18/04/202407:30GlobeNewswire Inc.IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
11/04/202407:00GlobeNewswire Inc.IMUNON Reports Compliance with Nasdaq Listing RequirementsNASDAQ:IMNNImunon Inc
28/03/202407:00GlobeNewswire Inc.IMUNON Reports 2023 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
25/03/202407:30GlobeNewswire Inc.IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesNASDAQ:IMNNImunon Inc
21/03/202416:00GlobeNewswire Inc.IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024NASDAQ:IMNNImunon Inc
13/03/202407:00GlobeNewswire Inc.IMUNON Files IND Application to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
12/03/202416:00GlobeNewswire Inc.IMUNON Announces Leadership ChangeNASDAQ:IMNNImunon Inc
29/02/202407:30GlobeNewswire Inc.Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5NASDAQ:IMNNImunon Inc
27/02/202407:30GlobeNewswire Inc.Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
22/02/202407:00GlobeNewswire Inc.IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineNASDAQ:IMNNImunon Inc
09/02/202415:09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IMNNImunon Inc
20/12/202316:15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IMNNImunon Inc
11/12/202315:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
11/12/202315:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
11/12/202307:30GlobeNewswire Inc.IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMNNImunon Inc
14/11/202308:00GlobeNewswire Inc.IMUNON’s VP of R&D to Present at the Vaccines Summit-2023NASDAQ:IMNNImunon Inc
14/11/202307:00GlobeNewswire Inc.IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:IMNNImunon Inc
07/11/202307:30GlobeNewswire Inc.IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023NASDAQ:IMNNImunon Inc
23/10/202307:30GlobeNewswire Inc.IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines CongressNASDAQ:IMNNImunon Inc
19/10/202307:30GlobeNewswire Inc.IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United NationsNASDAQ:IMNNImunon Inc
18/10/202307:30GlobeNewswire Inc.IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
06/10/202307:30GlobeNewswire Inc.IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory BoardNASDAQ:IMNNImunon Inc
28/09/202307:30GlobeNewswire Inc.IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
26/09/202307:30GlobeNewswire Inc.IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and TechnologiesNASDAQ:IMNNImunon Inc
13/09/202307:30GlobeNewswire Inc.IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ETNASDAQ:IMNNImunon Inc
07/09/202315:30GlobeNewswire Inc.IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ETNASDAQ:IMNNImunon Inc
05/09/202307:30GlobeNewswire Inc.IMUNON to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:IMNNImunon Inc
 Showing the most relevant articles for your search:NASDAQ:IMNN

Su Consulta Reciente

NYSE
VZ
Verizon Communications
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
AMEX
SPY
SPDR S&P 500
FX
EURMXN
Euro vs MXN
AMEX
XLE
Energy Select Sector SPDR
NYSE
MCD
McDonalds
AMEX
XLF
Financial Select Sector
CCOM
SILVER
SILVER
NYSE
NKE
Nike
CCOM
OILBRENT
Brent Oil
NYSE
BAC
Bank of America
AMEX
XLV
Health Care Select Sector
NASDAQ
NVDA
NVIDIA
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados